Abstract
Cardiac disease is the leading cause of mortality in America (1). Treatment employs lifestyle changes and medical therapeutics as primary methods of combating cardiac disease. The pharmaceutical armamentarium designed to treat the various aspects and incarnations of cardiovascular disease is vast (2,3). The use of potent and often multiple drug therapies necessitate vigilant treatment of the cardiac patient. Many of these drugs impact on nutritional status in both acute and chronic settings. Often, the impact is seen in adverse reactions and drug-nutrient interactions (DNIs) (4,5). Acute reactions, such as nausea and abdominal pain, affecting food intake may adversely affect nutritional status, whereas specific DNIs may have diffuse effects on pharmacokinetics such as drug bioavailability or drug clearance. Carbohydrate, protein, and lipid metabolism may all be altered as a consequence of cardiac pharmacotherapy. Although many interactions have been identified, the clinical relevance of these interactions is not always evident, so the physician should remain aware of all consequences of prescribed regimens.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
NHLBI morbidity and mortality chartbook. National Heart, Lung and Blood Institute, Bethesda, MD, 2002.
NHLBI fact book, fiscal year 2002. National Heart, Lung and Blood Institute, Bethesda, MD, 2003.
Gavagan T. Cardiovascular disease. Prim Care 2002; 29 (2): 323–338
Chan LN. Drug-nutrient interaction in clinical nutrition. Curr Opin Nutr Metab Care 2002; 5 (3): 327–332
Schmidt LE. Food-drug interactions. Drugs 2002; 62 (10): 1481–1502.
Horwich TB, Fonarow GC. The impact of obesity on survival in patients with heart failure. Heart Fail Monit 2002; 3 (1): 8–14.
Meyyazhagan S, Palmer RM. Nutritional requirement with aging. Prevention of disease. Clin Geriatr Med 2002; 18 (3): 557–576.
Tannen RL. Diuretic induced hypokalemia. Kidney Int 1985; 28: 988–1000.
McCrindle JL, Li kam Wa TC, Barron W, Prescott, LF. Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol 1996; 42 (6): 743–746.
Beerman B, Midskov C. Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol 1986; 29 (6): 725–727.
Morgan TO. Clinical use of potassium supplements and potassium sparing diuretics. Drugs 1973; 6 (3): 222–229.
Miller. Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am J. Cardiol 1987; 60: 17E–23E.
Brown MJ. Hypokalemia from 02-receptor stimulation by circulating epinephrine. Am J Cardiol 1985; 56: 3D–9D.
Shapiro LE. Drug Interactions: Protein, Pumps and P-450s. J Am Acad Dermatol 2002; 47 (4): 467–484.
Ueno K, Kawashima S, Uemoto K, et al. Effect of food on nifedipine sustained-release preparation. DICP 1989; 23 (9): 662–665.
Armstrong J, Challenor VF, Macklin BS, Renwick AG, Waller DG. The influence of two types of meal on the pharmacokinetics of a modified release formulation of nifedipine (Adalat retard). Eur J Clin Pharmacol 1997; 53 (2): 141–143.
Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled release formulation of nifedipine. Am J Med 1987; 83 (6B): 10–14.
Bailey DG. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337 (8736): 268–269.
Adigun AQ, Mudasiru Z. Clinical effects of grapefruit juice-nifedipine interaction in a 54 year old Nigerian: a case report. J Natl Med Assoc 2002; 94 (4): 276–278.
Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ 2002; 167 (3): 279–280.
Zaidenstein R. The effect of grapfruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994; 49 (9): 675–679.
Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000; 38 (4): 168–179.
Melander MN, Danielson K, hanson A, et al. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther 1977; 22 (1): 104–107.
Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther 1984; 36 (1): 14–18.
Horsmans Y. Different metabolism of statins: importance of drug-drug interactions. Eur Heart J 1999; 1 (suppl T): T7–T12.
Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999; 131 (5): 363–375.
Desouza C. Drugs affecting homocysteine metabolism. Drugs 2002; 62 (4): 605–616.
Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999; 354: 219–220.
de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine. Lancet 1999; 353 (9148): 209–210.
Cheng TO. St. John’s wort interaction with digoxin. Arch Intern Med 2000; 160: 2548.
Pohle T, Brzozowski T, Becker JC, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Alim Pharm and Ther 2001; 15 (5): 677–687.
Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57 (13): 1221–1227.
Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin in Lipidology 2003; 14 (1): 9–14.
Wong SS, Nahin RL, Richard L. National center for complementary and alternative medicine. Perspective for complementary and alternative medicine research in cardiovascular disease. Cardiology in Rev 2003; 11 (2): 94–98.
Hardman JG, Limbard LE, Gilman AG. Goodman and Gilman’s The pharmacological basis of therapeutics. 2001, Tenth edition. McGraw-Hill, New York, NY.
Deglin JH, Vallerand AH. Davis’s drug guide for nurses. 2002, Eighth edition. F.A. Davis Co., Philadelphia, PA.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Poblete, H.M., Talucci, R.C. (2004). Cardiac Drugs and Nutritional Status. In: Boullata, J.I., Armenti, V.T. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-781-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-59259-781-9_14
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5359-2
Online ISBN: 978-1-59259-781-9
eBook Packages: Springer Book Archive